Anticancer Mechanisms

Primary anti-cancer mechanisms of aspirin and why it remains a serious repurposing candidate

Aspirin is mechanistically unusual because it does not depend on one pathway alone.

Its anticancer relevance appears to come from several overlapping effects. That breadth is one reason it remains a credible repurposing candidate.

Special report

Featured deep dive

Aspirin and Thromboxane A2 (TXA2) explains one of aspirin's most important anti-metastatic mechanisms.

It covers platelet shielding, immune evasion, the TXA2 → ARHGEF1 → CD8+ T-cell axis, and how to judge when platelet or TXA2 biology is likely to matter in a real patient.

Primary mechanisms

1. COX inhibition

inhibits COX-1 and COX-2
reduces prostaglandin-driven inflammation
may weaken tumour growth, angiogenesis, and immune evasion

2. Platelet-mediated metastasis suppression

reduces platelet activation through thromboxane A2 suppression
weakens platelet shielding of circulating tumour cells
may reduce metastatic seeding

3. Immune surveillance support

may improve tumour antigen presentation
may reduce immune suppression within the tumour microenvironment
supports immunotherapy-combination interest

4. p53 and cell-cycle effects

may activate p53-related pathways in some models
may increase growth arrest and apoptosis signals
may work alongside broader cell-cycle control effects

5. DNA repair and genomic-stability effects

affects proteins linked to replication stress and repair
may improve net genomic control in selected settings
remains more mechanistic than clinically established

6. PI3K-pathway relevance in colorectal cancer

may preferentially benefit PIK3CA-altered colorectal cancer
likely matters through downstream inflammatory and survival signalling linked to the PI3K / AKT / mTOR pathway
now has prospective clinical support in biomarker-selected CRC

See Colorectal Cancer for the fuller clinical context.

7. Wnt / β-catenin and inflammatory pathway modulation

may suppress β-catenin / TCF signalling
may reduce IL-6 / STAT3 inflammatory pressure
gives aspirin broader gastrointestinal-oncology relevance

8. Epigenetic and microRNA effects

may influence histone-related regulation
may activate tumour-suppressive microRNA programs
could matter in p53-deficient settings

9. Anti-angiogenic effects

may reduce tumour-supporting vascular signalling
appears relevant in some colon and haematologic models
this mechanism is supportive, not the main story

Practical interpretation

Aspirin's strength is its breadth.

It targets inflammation, immune escape, platelet-assisted metastasis, and tumour signalling at the same time.

Its most practice-relevant mechanism today is the PI3K-pathway signal in selected colorectal cancer.

That still does not make aspirin a proven general cancer therapy. It does make aspirin more than a broad anti-inflammatory hypothesis.

Key References

Thun MJ et al. (2014). Molecular targets of aspirin and cancer prevention (COX-dependent and independent pathways, protein acetylation). British Journal of Cancer 111(1):61–67. https://www.nature.com/articles/bjc2014271[^8]
Piazza GA et al. (2013). COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Frontiers in Oncology 3:181. https://pmc.ncbi.nlm.nih.gov/articles/PMC3708159/[^9]
Ng K et al. (2024). Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Perspectives (COX-2 inhibition, TIGIT suppression, ER stress, apoptosis). Pharmaceutics 17(2):225. https://pmc.ncbi.nlm.nih.gov/articles/PMC11866938/[^10]
Pathi S et al. (2023). Aspirin and the metabolic hallmark of cancer (Wnt, NF-κB, mTOR/HIF-1α targeting). Exploration of Targeted Anti-tumor Therapy 4(5). https://www.explorationpub.com/Journals/etat/Article/1002155[^11]
Stark LA et al. (2017). Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus. Biomedicines 5(3):43. https://pmc.ncbi.nlm.nih.gov/articles/PMC5618301/[^12]
Turini ME & DuBois RN (2006). Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a COX-independent mechanism. FASEB J 20(12):2009–16. https://pubmed.ncbi.nlm.nih.gov/17012253/[^13]
Deng L et al. (2024). Exploring Aspirin's Potential in Cancer Prevention (COX-1/2 inhibition, PI3K/AKT, ERK pathways, apoptosis induction). Biomolecules 14(10):1320. https://pmc.ncbi.nlm.nih.gov/articles/PMC11498354/[^14]

Ricci F et al. (2012). Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. ISRN Oncology 2012:260705. https://pmc.ncbi.nlm.nih.gov/articles/PMC3816673/[^15]

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.